Breakthroughs in SARS-CoV-2-monoclonal antibodies development
In December 2019, cases of unknown pneumonia-like disease connected to food markets were reported in China. The causative agent was identified as a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2), and the disease which spread all over the world, was named COVID-19. This pandemic has neg...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
ResearchersLinks, Ltd
2021-02-01
|
| Series: | Novel Research in Microbiology Journal |
| Subjects: | |
| Online Access: | https://nrmj.journals.ekb.eg/article_149375_ca43e278ae9d981f574bef2edd5da549.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | In December 2019, cases of unknown pneumonia-like disease connected to food markets were reported in
China. The causative agent was identified as a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2), and the disease which spread all over the world, was named COVID-19. This pandemic has negatively
affected quality of life and economy worldwide, thus motivating thoughtful search for treatment and prevention
strategies. Efforts have been made in drug repositioning and vaccine development as well as development of
monoclonal antibodies. Monoclonal antibodies provide a long-lasting protective immunity against the pathogens,
and have been at the forefront line in the therapy of some viral diseases. This study aimed to review the advances
in SARS-CoV-2 monoclonal antibodies (mAbs) development. Most of the developed SARS-CoV-2 monoclonal
antibodies including; B38, CR3022, 47D11, and H4, have targeted the spike protein of the virus to prevent its
interaction with the host cell ACE-2 receptor. However, others such as Tocilizumab prevent the inflammation
caused by the cytokine storm. |
|---|---|
| ISSN: | 2537-0286 2537-0294 |